Clinical Scorecard: The Role of Bispecific Antibodies in Managing Multiple Myeloma
At a Glance
Category
Detail
Condition
Multiple Myeloma (MM)
Key Mechanisms
Bispecific antibodies (BsAbs) engage T cells to lyse MM cells by binding tumor-specific antigens and T-cell CD3 co-receptor, activating T-cell mediated apoptosis.
Target Population
Heavily pre-treated MM patients, including those refractory to CD38 monoclonal antibodies and multiple lines of therapy.
Care Setting
Oncology clinics and specialized hematology centers managing relapsed/refractory MM.
Key Highlights
BsAbs show deep and sustained responses in heavily pre-treated, refractory MM patients with manageable side effects including infections and low-grade cytokine release syndrome.
Approved BsAbs target plasma cell antigens such as BCMA and GPRC5D, with ongoing development of agents targeting FcRH5 and others.
BsAbs offer off-the-shelf availability and potential for combination or earlier line use to improve MM outcomes.
Guideline-Based Recommendations
Diagnosis
Identify MM patients refractory to standard therapies including CD38 Mo-Abs, proteasome inhibitors, and IMiDs.
Assess expression of target antigens such as BCMA and GPRC5D on malignant plasma cells.
Management
Use FDA-approved BsAbs like teclistamab (anti-BCMA) and talquetamab (anti-GPRC5D) in relapsed/refractory MM.
Consider BsAbs for patients with penta-refractory disease to improve progression-free survival.
Monitor and manage predictable side effects including infections and low-grade cytokine release syndrome.
Monitoring & Follow-up
Regularly evaluate treatment response and disease progression using clinical and biomarker assessments.
Monitor for adverse events such as infections and cytokine release syndrome during BsAb therapy.
Risks
Risk of infections due to immune modulation.
Potential for cytokine release syndrome, generally low grade and manageable.
Possible reduced efficacy related to antigen shedding (noted with BCMA but less with GPRC5D).
Patient & Prescribing Data
Patients with multiple myeloma refractory to multiple prior therapies including CD38 monoclonal antibodies, proteasome inhibitors, and IMiDs.
BsAbs demonstrate promising efficacy with deep and sustained responses; manageable safety profile supports their use as add-on or subsequent therapy.
Clinical Best Practices
Select BsAb therapy based on antigen expression profile and prior treatment history.
Monitor closely for cytokine release syndrome and infections, initiating supportive care promptly.
Consider combination strategies or earlier integration of BsAbs to enhance efficacy.
Use biomarkers such as soluble BCMA levels to assess disease activity and prognosis.
Educate patients on potential side effects and the importance of adherence to monitoring schedules.
